Endovia Health Sciences, Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Endovia Health Sciences (formerly Splash Beverage, ~$6.5M market cap) announced the U.S. FDA established Investigational New Animal Drug (INAD) File No. 14145 for its CannEpil program on August 25, 2026, marking the first regulatory milestone under its collaboration with Lupvindol Biosciences Ltd. CannEpil is a cannabinoid formulation (CBD/THC isolates) targeting cancer-related pain in companion animals, initially focusing on canine oncology, and will pursue the FDA's Minor Use/Minor Species (MUMS) Conditional Approval pathway. No specific dollar amounts, timelines, or study details were disclosed.
Why this rating
INAD establishment is real validation of pipeline; meaningful relative to $6.5M cap. Execution risk remains high; regulatory pathway uncertain, capital needs large, no revenue timeline disclosed.
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.